Save billions or stick with Humira? Drug brokers steer Americans to the costly choice

Tennessee last year spent $48 million on a single drug, Humira—about $62,000 for each of the 775 patients who were covered by its employee health insurance program and receiving the treatment. So when nine Humira knockoffs, known as biosimilars, hit the market for as little as $995 a month, the opportunity for savings appeared ample and immediate.